Retinal Degeneration Clinical Trial
Official title:
French Translation and Validation of the Michigan Retinal Degeneration Questionnaire and the Michigan Vision-Related Anxiety Questionnaire in a Cohort of People With Hereditary Retinal Degeneration.
While inherited retinal diseases are well characterized anatomically and functionally, it is also essential to understand their impact on patients' quality of life, from their ability to perform the tasks of daily living to the psychological impact of the disease on patients. Questionnaires (PRO, Patient-Reported Outcomes) are important tools for assessing this impact. However, PROs validated in French are rare, and often poorly adapted to populations with hereditary retinal degeneration. New PROs particularly adapted to retinal degeneration have recently been validated in English: the Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Validation of a French translation will provide a standardized, reliable tool for French-speaking patients, and enable these questionnaires to be used in gene therapy clinical trials, to assess the efficacy of treatments and their impact on patients' quality of life.
Interventional research of category 2 with minimal risks and constraints. This is a prospective, monocentric, longitudinal, non-randomized study to validate the translation of questionnaires to assess abilities in daily living tasks and the potential psychological repercussions of visual impairment in various hereditary retinal dystrophies. The research will be conducted in two distinct phases: Comprehension phase and validation phase ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
| Terminated |
NCT03561922 -
Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS
|
N/A | |
| Active, not recruiting |
NCT03872479 -
Single Ascending Dose Study in Participants With LCA10
|
Phase 1/Phase 2 | |
| Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
| Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
| Active, not recruiting |
NCT01736293 -
Natural History of Eye Diseases Related to ABCA4 Mutations
|
||
| Completed |
NCT03318549 -
BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases
|
N/A | |
| Completed |
NCT04919473 -
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
| Completed |
NCT03321253 -
Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification
|
N/A | |
| Completed |
NCT01497379 -
Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
|
N/A | |
| Recruiting |
NCT04620876 -
Bimodal and Coaxial High Resolution Ophtalmic Imaging
|
N/A | |
| Recruiting |
NCT03592017 -
Performance of Long-wavelength Autofluorescence Imaging
|
N/A | |
| Completed |
NCT03150654 -
The Effect of Laser Treatment on Macular Pigment of Eye in Cases With Diabetes
|
N/A | |
| Recruiting |
NCT04545736 -
Oral Metformin for Treatment of ABCA4 Retinopathy
|
Phase 1/Phase 2 | |
| Completed |
NCT00403195 -
Clinical and Pathophysiological Description of Ocular Ischemic Syndrome
|
N/A | |
| Enrolling by invitation |
NCT06167642 -
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
|
||
| Enrolling by invitation |
NCT02144103 -
Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06289452 -
Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis
|
Early Phase 1 | |
| Recruiting |
NCT02617966 -
Rod and Cone Mediated Function in Retinal Disease
|
||
| Recruiting |
NCT04855045 -
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
|
Phase 2/Phase 3 |